By 2020, Africa may well represent a US$ 65-billion opportunity for drug manufacturers. This is due to several factors, including increasing urbanization, a disproportionate disease burden, a projected rise in chronic illnesses across the continent, and greater international attention to the health challenges facing the African people.
Africa’s pharmaceutical potential, as well as tips on how to best capitalize on it, are detailed in an article written by John-Paul Iwuoha and posted on the SmallStarter website. The article, titled “Meet the Multi-Billion Dollar Opportunity to Fight Diseases in Africa”, cities a McKinsey & Company report that declares that Africa may well represent the only pharmaceutical market where high rates of growth are still possible.
Special thanks to Admasu, who shared this article with the IFAPP LinkedIn Group. If you haven’t already, be sure to join our group and take part in discussions on the issues of utmost importance to the pharmaceutical and medicines development industry.